Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Clinical Research Institute, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Curr Stem Cell Res Ther. 2022;17(8):825-838. doi: 10.2174/1574888X16666211007092055.
The efficacy of mesenchymal stem cell (MSC) therapy in acetaminophen-induced liver injury has been investigated in animal experiments, but individual studies with a small sample size cannot be used to draw a clear conclusion. Therefore, we conducted a systematic review and meta-analysis of preclinical studies to explore the potential of using MSCs in acetaminophen- induced liver injury.
Eight databases were searched for studies reporting the effects of MSCs on acetaminophen hepatoxicity. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were used. SYRCLE's risk of bias tool for animal studies was applied to assess the methodological quality. A meta-analysis was performed by using RevMan 5.4 and STATA/ SE 16.0 software.
Eleven studies involving 159 animals were included according to PRISMA statement guidelines. Significant associations were found for MSCs with the levels of alanine transaminase (ALT) (standardized mean difference (SMD) - 2.58, p < 0.0001), aspartate aminotransferase (AST) (SMD - 1.75, p = 0.001), glutathione (GSH) (SMD 3.7, p < 0.0001), superoxide dismutase (SOD) (SMD 1.86, p = 0.022), interleukin 10 (IL-10) (SMD 5.14, p = 0.0002) and tumor necrosis factor-α (TNF-α) (SMD - 4.48, p = 0.011) compared with those in the control group. The subgroup analysis showed that the tissue source of MSCs significantly affected the therapeutic efficacy (p < 0.05).
Our meta-analysis results demonstrate that MSCs could be a potential treatment for acetaminophen- related liver injury. The protocol for this meta-analysis was prospectively registered in PROSPERO (Number: CRD42020212677).
间充质干细胞（MSC）疗法在对乙酰氨基酚诱导的肝损伤中的疗效已在动物实验中进行了研究，但由于个体研究样本量小，无法得出明确结论。因此，我们对临床前研究进行了系统评价和荟萃分析，以探讨 MSC 在对乙酰氨基酚诱导的肝损伤中的应用潜力。
在八个数据库中搜索了报告 MSC 对乙酰氨基酚肝毒性影响的研究。使用系统评价和荟萃分析的首选报告项目（PRISMA）指南。应用 SYRCLE 动物研究偏倚风险工具评估方法学质量。使用 RevMan 5.4 和 STATA/SE 16.0 软件进行荟萃分析。
根据 PRISMA 声明指南，有 11 项研究涉及 159 只动物被纳入。发现 MSC 与丙氨酸转氨酶（ALT）（标准化均数差（SMD）-2.58，p<0.0001）、天冬氨酸转氨酶（AST）（SMD-1.75，p=0.001）、谷胱甘肽（GSH）（SMD 3.7，p<0.0001）、超氧化物歧化酶（SOD）（SMD 1.86，p=0.022）、白细胞介素 10（IL-10）（SMD 5.14，p=0.0002）和肿瘤坏死因子-α（TNF-α）（SMD-4.48，p=0.011）水平显著相关。亚组分析表明，MSC 的组织来源显著影响治疗效果（p<0.05）。
我们的荟萃分析结果表明，MSC 可能是一种潜在的对乙酰氨基酚相关肝损伤治疗方法。本荟萃分析的方案在 PROSPERO（编号：CRD42020212677）中进行了前瞻性注册。
